These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31996670)

  • 1. Modeling medulloblastoma in vivo and with human cerebellar organoids.
    Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
    Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.
    Bunt J; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
    PLoS One; 2011; 6(10):e26058. PubMed ID: 22016811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A group 3 medulloblastoma stem cell program is maintained by OTX2-mediated alternative splicing.
    Saulnier O; Zagozewski J; Liang L; Hendrikse LD; Layug P; Gordon V; Aldinger KA; Haldipur P; Borlase S; Coudière-Morrison L; Cai T; Martell E; Gonzales NM; Palidwor G; Porter CJ; Richard S; Sharif T; Millen KJ; Doble BW; Taylor MD; Werbowetski-Ogilvie TE
    Nat Cell Biol; 2024 Aug; 26(8):1233-1246. PubMed ID: 39025928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma.
    Wortham M; Guo C; Zhang M; Song L; Lee BK; Iyer VR; Furey TS; Crawford GE; Yan H; He Y
    PLoS One; 2014; 9(9):e107156. PubMed ID: 25198066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma.
    Stromecki M; Tatari N; Morrison LC; Kaur R; Zagozewski J; Palidwor G; Ramaswamy V; Skowron P; Wölfl M; Milde T; Del Bigio MR; Taylor MD; Werbowetski-Ogilvie TE
    Mol Oncol; 2018 Apr; 12(4):495-513. PubMed ID: 29377567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines.
    Bunt J; de Haas TG; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
    Mol Cancer Res; 2010 Oct; 8(10):1344-57. PubMed ID: 21047732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma.
    Qin N; Paisana E; Picard D; Leprivier G; Langini M; Custódia C; Cascão R; Conrad C; Peitzsch M; Stefanski A; Stühler K; Fischer U; Faria CC; Dietrich S; Reifenberger G; Remke M
    J Neurooncol; 2023 Nov; 165(2):329-342. PubMed ID: 37976029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma.
    Boulay G; Awad ME; Riggi N; Archer TC; Iyer S; Boonseng WE; Rossetti NE; Naigles B; Rengarajan S; Volorio A; Kim JC; Mesirov JP; Tamayo P; Pomeroy SL; Aryee MJ; Rivera MN
    Cancer Discov; 2017 Mar; 7(3):288-301. PubMed ID: 28213356
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the enhancer of zeste homologue 2 in medulloblastoma.
    Alimova I; Venkataraman S; Harris P; Marquez VE; Northcott PA; Dubuc A; Taylor MD; Foreman NK; Vibhakar R
    Int J Cancer; 2012 Oct; 131(8):1800-9. PubMed ID: 22287205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation.
    Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C
    Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis.
    van Essen MJ; Apsley EJ; Riepsaame J; Xu R; Northcott PA; Cowley SA; Jacob J; Becker EBE
    Dis Model Mech; 2024 Feb; 17(2):. PubMed ID: 38411252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The
    Ampudia-Mesias E; Cameron CS; Yoo E; Kelly M; Anderson SM; Manning R; Abrahante Lloréns JE; Moertel CL; Yim H; Odde DJ; Saydam N; Saydam O
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells.
    Kaur R; Aiken C; Morrison LC; Rao R; Del Bigio MR; Rampalli S; Werbowetski-Ogilvie T
    Dis Model Mech; 2015 Oct; 8(10):1295-309. PubMed ID: 26398939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate.
    Zagozewski J; Shahriary GM; Morrison LC; Saulnier O; Stromecki M; Fresnoza A; Palidwor G; Porter CJ; Forget A; Ayrault O; Hawkins C; Chan JA; Vladoiu MC; Sundaresan L; Arsenio J; Taylor MD; Ramaswamy V; Werbowetski-Ogilvie TE
    Nat Commun; 2020 Jul; 11(1):3627. PubMed ID: 32686664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.
    Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development.
    Shi X; Wang Q; Gu J; Xuan Z; Wu JI
    Oncogene; 2016 Nov; 35(44):5746-5758. PubMed ID: 27065321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
    Ciccone R; Quintarelli C; Camera A; Pezzella M; Caruso S; Manni S; Ottaviani A; Guercio M; Del Bufalo F; Quadraccia MC; Orlando D; Di Cecca S; Sinibaldi M; Aurigemma M; Iaffaldano L; Sarcinelli A; D'Amore ML; Ceccarelli M; Nazio F; Marabitti V; Giorda E; Pezzullo M; De Stefanis C; Carai A; Rossi S; Alaggio R; Del Baldo G; Becilli M; Mastronuzzi A; De Angelis B; Locatelli F
    Clin Cancer Res; 2024 Jun; 30(11):2545-2557. PubMed ID: 38551501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
    Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
    J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.